Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Triple Negative Breast Cancers: early-phase trial registry
1 of 2 indexed Metastatic Triple Negative Breast Cancers trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Metastatic Triple Negative Breast Cancers: 2 US clinical trials tracked, 1 recruiting.
Metastatic Triple Negative Breast Cancers is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is BioNTech SE, running 1 of these trials.
Enrollment posture brief
Registry condition metastatic-triple-negative-breast-cancers
OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Metastatic Triple Negative Breast Cancers lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Triple Negative Breast Cancers on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Triple Negative Breast Cancers is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
University of California, San Francisco
NCT06774027
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
BioNTech SE
NCT06449222
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Triple Negative Breast Cancers records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Triple Negative Breast Cancers trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Triple Negative Breast Cancers page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Metastatic Triple Negative Breast Cancers trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- BioNTech SE sponsors the most Metastatic Triple Negative Breast Cancers trials on record, review their full trial history before evaluating a specific study. See BioNTech SE's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Triple Negative Breast Cancers condition card totals 2 registered trials; most-linked intervention Nab-placlitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.